82611-49-2 Usage
General Description
D-Lysine, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-, methyl ester is a chemical compound that is a derivative of the amino acid lysine. It is formed by the addition of a methyl ester group to the lysine molecule, as well as the addition of protective groups at the N2 and N6 positions. These protective groups are used to prevent unwanted reactions at these sites and to allow for selective reactions at other functional groups within the molecule. D-Lysine, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-, methyl ester may be used in chemical synthesis, particularly in the production of peptide or protein derivatives, where the protection of certain functional groups is necessary in order to achieve specific chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 82611-49-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,6,1 and 1 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 82611-49:
(7*8)+(6*2)+(5*6)+(4*1)+(3*1)+(2*4)+(1*9)=122
122 % 10 = 2
So 82611-49-2 is a valid CAS Registry Number.
InChI:InChI=1/C20H30N2O6/c1-20(2,3)28-19(25)22-16(17(23)26-4)12-8-9-13-21-18(24)27-14-15-10-6-5-7-11-15/h5-7,10-11,16H,8-9,12-14H2,1-4H3,(H,21,24)(H,22,25)/t16-/m1/s1
82611-49-2Relevant articles and documents
PCSK9 ANTAGONIST COMPOUNDS
-
Page/Page column 88; 89, (2021/03/05)
Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
